SPECT imaging of fibrin using fibrin-binding peptides

Contrast Media and Molecular Imaging

Volumn 8, Issue 3, 2013, Pages 229-237

  Starmans, Lucas W E ^a   Van Duijnhoven, Sander M J ^a   Rossin, Raffaella ^b   Aime, Silvio ^c   Daemen, Mat J A P ^d   Nicolay, Klaas ^a   Grüll, Holger ^a,b  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c UNIVERSITY OF TURIN   (Italy)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Fibrin; Molecular imaging; Peptides; SPECT; Thrombus

Indexed keywords

FIBRIN; FIBRIN BINDING PEPTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD CLOT; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; CAROTID ARTERY THROMBOSIS; FIBRIN; INDIUM RADIOISOTOPES; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MOLECULAR IMAGING; PEPTIDES; PROTEIN BINDING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84876815315     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1521     Document Type: Article

References (39)

1. Turpie AG, Esmon C. Venous and arterial thrombosis - pathogenesis and the rationale for anticoagulation. Thromb Haemost 2011; 105(4): 586-596.
2. Burns SK, Haramati LB. Diagnostic imaging and risk stratification of patients with acute pulmonary embolism. Cardiol Rev 2012; 20(1): 15-24.
3. Elliott CG, Lovelace TD, Brown LM, Adams D. Diagnosis: imaging techniques. Clin Chest Med 2010; 31(4): 641-657.
4. Constantinides P. Cause of thrombosis in human atherosclerotic arteries. Am J Cardiol 1990; 66(16): 37G-40G.
5. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. New Engl J Med 2003; 349(24): 2316-2325.
6. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003; 124(3 suppl): 58S-68S.
7. Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, Yeo TK, Dvorak AM, van de Water L, Sioussat TM, Senger DR. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann NY Acad Sci 1992; 667: 101-111.
8. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105(1): 178-185.
9. Yasunaga M, Manabe S, Matsumura Y. New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Cancer Sci 2011; 102(7): 1396-1402.
10. Morris TA, Marsh JJ, Chiles PG, Konopka RG, Pedersen CA, Schmidt PF, Gerometta M. Single photon emission computed tomography of pulmonary emboli and venous thrombi using anti-D-dimer. Am J Respir Crit Care Med 2004; 169(9): 987-993.
11. Morris TA, Gerometta M, Smart RC, Eisenberg P, Roach PJ, Tsui WW, Better N, Taubman KL, Unger SA, Macfarlane D. Pulmonary emboli imaging with (99m)Tc-labelled anti-D-dimer (DI-80B3) Fab' followed by SPECT. Heart Lung Circul 2011; 20(8): 503-511.
12. 99mTc-labeled fibrin alpha-chain peptide. J Nucl Med 2000; 41(1): 161-168.
13. Aruva MR, Daviau J, Sharma SS, Thakur ML. Imaging Thromboembolism with Fibrin-Avid 99mTc-Peptide: evaluation in Swine. J Nucl Med 2006; 47(1): 155-162.
14. Spuentrup E, Botnar RM, Wiethoff AJ, Ibrahim T, Kelle S, Katoh M, Ozgun M, Nagel E, Vymazal J, Graham PB, Gunther RW, Maintz D. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol 2008; 18(9): 1995-2005.
15. Sirol M, Fuster V, Badimon JJ, Fallon JT, Moreno PR, Toussaint JF, Fayad ZA. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 2005; 112(11): 1594-1600.
16. Botnar RM, Perez AS, Witte S, Wiethoff AJ, Laredo J, Hamilton J, Quist W, Parsons EC, Jr., Vaidya A, Kolodziej A, Barrett JA, Graham PB, Weisskoff RM, Manning WJ, Johnstone MT. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 2004; 109(16): 2023-2029.
17. Vymazal J, Spuentrup E, Cardenas-Molina G, Wiethoff AJ, Hartmann MG, Caravan P, Parsons EC, Jr. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol 2009; 44(11): 697-704.
18. Spuentrup E, Buecker A, Katoh M, Wiethoff AJ, Parsons EC, Jr., Botnar RM, Weisskoff RM, Graham PB, Manning WJ, Gunther RW. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 2005; 111(11): 1377-1382.
19. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am College Cardiol 2009; 53(18): 1621-1628.
20. Marinelli E, Ramalingam K, Swenson R, Song B, Lattuada L, Uggeri F, Lorusso V, Aime S, Morosini P, Chaabane L, Bracco Imaging SpA. Fibrin binding peptide conjugates for diagnostic and therapeutic applications. Patent WO 2008/071679 A1, 2008.
21. Sachs UJH, Nieswandt B. In vivo thrombus formation in murine models. Circul Res 2007; 100(7): 979-991.
22. von zur Muhlen C, von Elverfeldt D, Moeller JA, Choudhury RP, Paul D, Hagemeyer CE, Olschewski M, Becker A, Neudorfer I, Bassler N, Schwarz M, Bode C, Peter K. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 2008; 118(3): 258-267.
23. Miserus RJ, Herias MV, Prinzen L, Lobbes MB, Van Suylen RJ, Dirksen A, Hackeng TM, Heemskerk JW, van Engelshoven JM, Daemen MJ, van Zandvoort MA, Heeneman S, Kooi ME. Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovasc Imag 2009; 2(8): 987-996.
24. Heidt T, Deininger F, Peter K, Goldschmidt J, Pethe A, Hagemeyer CE, Neudorfer I, Zirlik A, Weber WA, Bode C, Meyer PT, Behe M, von zur Mühlen C. Activated platelets in carotid artery thrombosis in mice can be selectively targeted with a radiolabeled single-chain antibody. PLoS One 2011; 6(3): e18446.
25. Overoye-Chan K, Koerner S, Looby RJ, Kolodziej AF, Zech SG, Deng Q, Chasse JM, McMurry TJ, Caravan P. EP-2104R: a fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. J Am Chem Soc 2008; 130(18): 6025-6039.
26. Kolodziej AF, Nair SA, Graham P, McMurry TJ, Ladner RC, Wescott C, Sexton DJ, Caravan P. Fibrin specific peptides derived by phage display: characterization of peptides and conjugates for imaging. Bioconjug Chem 2012; 23(3): 548-556.
27. Smith DA, W Hvd, Walker DK. Pharmacokinetics and Metabolism in Drug Design. Wiley-VCH: Weinheim, 2006.
28. Makowski MR, Forbes SC, Blume U, Warley A, Jansen CH, Schuster A, Wiethoff AJ, Botnar RM. In vivo assessment of intraplaque and endothelial fibrin in ApoE(-/-) mice by molecular MRI. Atherosclerosis 2012; 222(1): 43-49.
29. Uppal R, Catana C, Ay I, Benner T, Sorensen AG, Caravan P. Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe - feasibility study in rat model. Radiology 2011; 258(3): 812-820.
30. Wescot CR, Beltzer JP, Sato AK, Dyax Corp. Fibrin binding moieties useful as imaging agents. Patent WO 02/055544 A2, 2002.
31. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002; 13(3): 530-541.
32. de Vries A, Custers E, Lub J, van den Bosch S, Nicolay K, Grull H. Block-copolymer-stabilized iodinated emulsions for use as CT contrast agents. Biomaterials 2010; 31(25): 6537-6544.
33. Uppal R, Medarova Z, Farrar CT, Dai G, Moore A, Caravan P. Molecular imaging of fibrin in a breast cancer xenograft mouse model. Invest Radiol 2012; 47(10): 553-558.
34. Heiba SI, Kolker D, Mocherla B, Kapoor K, Jiang M, Son H, Rangaswamy B, Kostakoglu L, Savitch I, DaCosta M, Machac J. The optimized evaluation of diabetic foot infection by dual isotope SPECT/CT imaging protocol. J Foot Ankle Surg 2010; 49(6): 529-536.
35. Hsieh PC, Lee IH, Yeh TL, Chen KC, Huang HC, Chen PS, Yang YK, Yao WJ, Lu RB, Chiu NT. Distribution volume ratio of serotonin and dopamine transporters in euthymic patients with a history of major depression - a dual-isotope SPECT study. Psychiat Res 2010; 184(3): 157-161.
36. 68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Sem Nucl Med 2011; 41(4): 314-321.
37. 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem 2010; 21(7): 1331-1340.
38. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007; 80(950): 73-76.
39. Institute of Laboratory Animal Resources (US) Committee on Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. NIH publication. US Department of Health and Human Services, Public Health Service: Bethesda, MD, 1985.